Once a patient is confirmed to have Parkinson’s Disease, what are the evidence- and guideline-based approaches to initiating pharmacotherapy and, sequencing therapy in cases that are refractory to initial therapy or that do not respond optimally?

Once a patient is confirmed to have Parkinson’s Disease, what are the evidence- and guideline-based approaches to initiating pharmacotherapy and, sequencing therapy in cases that are refractory to initial therapy or that do not respond optimally?

Once a patient is confirmed to have Parkinson’s Disease, what are the evidence- and guideline-based approaches to initiating pharmacotherapy and, sequencing therapy in cases that are refractory to initial therapy or that do not respond optimally?


Created by

CMEducation Resources iQ&A Parkinson’s Disease (PD) Medical Intelligence Zone

Related Presenters

Laxman Bahroo, DO, FAAN

Laxman Bahroo, DO, FAAN

Associate Professor, Department of Neurology Georgetown University Medical Center Vice Chair of Finance Director, Residency Program Director, Botulinum Toxin Clinic Associate Professor of Neurology Medstar Georgetown University HospitalWashington, D.C.